Could cause temporary or reversible harm; serious harm is unlikely.
Failed Dissolution Specifications: Product failed to meet dissolution acceptance criteria in the stability studies at the 6th month (25¿C/60% RH) long-term.
| Brand name | METOPROLOL SUCCINATE |
| Generic name | METOPROLOL SUCCINATE |
| Active ingredient(s) | METOPROLOL SUCCINATE |
| Distributed by / for | Granules Pharmaceuticals Inc., Chantilly, VA 20151 |
| NDC | 70010-780-01 |
| Full product label | Metoprolol Succinate Extended-Release Tablets, USP, 25 mg, Packaged in a) 100-count bottle, NDC 70010-780-01; b) 500-count bottle, NDC 70010-780-05; Rx only, Manufactured by: Granules India Limited, Hyderadab-500 081, India, Manufactured for: Granules Pharmaceuticals Inc., Chantilly, VA 20151, |
| Recalling firm | Granules Pharmaceuticals Inc. |
| Distribution | Nationwide in the USA. |
| Quantity | 27,648 100-count Bottles; 5,376 500-count Bottles |
| Recall initiated | 2025-06-24 |
| Report date | 2025-07-09 |
| Recall completed | — |
| Recall number | D-0510-2025 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Chantilly VA United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗